Whoop

WHOOP sells a wrist band with no screen, no notifications, and no way to use it without paying every month. That is the whole idea. Founder Will Ahmed, a former Harvard squash captain who kept overtraining without knowing it, read roughly 500 medical papers and came away convinced that around-the-clock heart-rate and HRV data could tell you when to push and when to rest.

The company launched in 2012 out of Boston and has spent more than a decade turning that thesis into hardware plus software. In March 2026 it closed a $575M Series G at a $10.1 billion valuation, nearly triple where it sat in 2021, with Cristiano Ronaldo, LeBron James, and Rory McIlroy putting their own money in alongside sovereign funds and the Mayo Clinic.

WHOOP straps a set of always-on sensors to your wrist and reads your body every second: sleep, strain, recovery, resting heart rate, HRV, and more, all day and all night. The band deliberately has no screen. Everything you see lives in the app, which turns the raw signal into a daily recovery score and personalized coaching on how hard to train and when to back off.

The pitch is a complete picture rather than a step counter. The company cites its own data that daily wear correlates with more weekly activity, more sleep, and higher HRV, and it keeps pushing into clinical territory with blood pressure insights, ECG readings, and women's hormonal tracking.

Plenty of devices show you a number. The harder problem WHOOP goes after is interpretation: are you recovered enough to train hard today, or are you one bad night from an injury? That was the exact question Will Ahmed could not answer as a college athlete, even with top coaching.

So the product is built around continuous physiological data feeding a recovery score and coaching, not a dashboard you have to decode yourself. The newer health features push further, from flagging irregular heart rhythms to helping members track how daily behavior maps to longevity.

WHOOP started with serious athletes and still leans on them hard, from pro football and Formula 1 teams to Olympians. That audience is the credibility engine. But the broader target is anyone willing to pay for structured feedback on sleep, stress, and training, whether they are a weekend runner or a biohacker tracking recovery.

The newer clinical features widen the aperture again toward health and longevity, aiming at people who care less about workout strain and more about heart health, hormones, and aging well.

The core product is the WHOOP band paired with a membership, and the two are inseparable: the hardware comes bundled with the plan rather than sold on its own. The 5.0 device runs 14-plus days on a charge and reads sleep, strain, recovery, and more.

On top of that sit the health layers members are actually paying up for: Healthspan and Pace of Aging, a real-time Stress Monitor, blood pressure insights, ECG-based heart screening, women's hormonal insights, and Advanced Labs, which analyzes 65-plus biomarkers against your WHOOP data.

WHOOP does not sell a gadget, it sells a subscription with a sensor attached. Membership starts at $199 a year, the device and charger are included, and the app, coaching, and analysis all stop the moment you cancel. That recurring revenue is the whole model, which is why the higher tiers keep adding clinical features worth paying more for.

Memberships are HSA/FSA eligible, and there is a one-month free trial plus family plans to widen the funnel.

WHOOP competes in a crowded wearables field against the Oura Ring, the Apple Watch, Garmin, and Fitbit, most of which sell a screen and a one-time purchase. WHOOP's counter-position is the screen-free, always-on band and a recovery-and-strain model that reviewers consistently call the most sophisticated of the bunch.

The catch is the same thing that differentiates it. Rivals let you buy once and own the device, while WHOOP locks you into a subscription, which is exactly the tradeoff skeptics push back on.

WHOOP leans hard on elite endorsement, and the roster is real: Cristiano Ronaldo, Rory McIlroy, Patrick Mahomes, Sha'Carri Richardson, and Virgil van Dijk all appear as members, with Paris Saint-Germain, Scuderia Ferrari HP, and other teams naming it their official health and fitness wearable.

The conviction runs deeper than logos. In the 2026 raise, Ronaldo, LeBron James, and Rory McIlroy invested their own money, which is a different signal than a sponsorship.

Across reviews and the WHOOP subreddit, the praise is consistent: the strain-and-recovery coaching is the best in class, the 14-day battery is a genuine edge, and members credit it with building real habits around sleep and stress. Athletes especially value it for avoiding overtraining.

The complaints are just as consistent. The mandatory subscription grates, heart-rate accuracy during high-intensity intervals and step tracking draw doubts, and several users call the service hard to cancel and slow to reach. The recurring verdict: worth it if you are serious, hard to justify if you are casual.

WHOOP raised a $575M Series G in March 2026 at a $10.1 billion valuation, up from $3.6 billion in its 2021 SoftBank-led Series F. Total raised sits around $900M.

The cap table reads like a mix of money and mission: Collaborative Fund led, with Mubadala, the Qatar Investment Authority, IVP, Foundry Group, Accomplice, and, notably, Abbott and the Mayo Clinic joining, plus athlete-investors Ronaldo, James, and McIlroy. The healthcare names hint at where the company thinks the value is heading.

The tell is in the cap table and the roadmap. Abbott and the Mayo Clinic joining the Series G, plus a product push into blood pressure, ECG, hormonal insights, and Healthspan, all point at WHOOP trying to graduate from a training tracker into a longevity and health platform.

The risk is unchanged since day one: the whole thing rests on people paying a subscription forever, and the loudest criticism is aimed squarely at that model. If the clinical features prove sticky, the lock-in becomes a moat. If they do not, it stays a sore point.

WHOOP describes itself as grounded in research, design, and privacy, with values that read like a startup that still moves fast: best idea wins, a bias for action, and, in its own words, the intersection of high intensity and high humility. Prior reporting pegs it around 500 employees, and the company says it hires only a tiny fraction of applicants.

The team works out of Boston and hires almost entirely on-site there, across engineering, machine learning, hardware, data, product, and design. Employee resource groups span disability inclusion, Black@WHOOP, LGBTQ+, veterans, women in science and engineering, and parents.

WHOOP discloses U.S. salary ranges on its roles and frames total comp as base plus meaningful equity plus benefits, with equity pitched as the differentiator that lets every corporate employee own part of the company. Disclosed engineering bands run widest, roughly $105K to $260K, with product, design, marketing, and operations bands published in USD.

Ranges vary by role, level, and location, and the company notes most offers land toward the lower end of the posted band.

The registered entity is Whoop, Inc., with a legal address at One Kenmore Square, #601, Boston, MA 02215, and privacy inquiries routed to privacy@whoop.com. Given that the product handles continuous physiological and health data, privacy sits at the center of both the company's stated values and its hiring, which includes dedicated privacy and product-security roles.

The company markets encrypted data storage for member health information, though it does not publish a public subprocessor list or named compliance certifications on the pages captured here.

WHOOP's headlines have tracked its climb: the 2021 SoftBank-led round that put it at $3.6 billion, and the 2026 Series G that nearly tripled that number to $10.1 billion. The recent coverage frames it as one of the more valuable standalone wearables companies, now pushing into clinical health.